<DOC>
	<DOCNO>NCT02636907</DOCNO>
	<brief_summary>This open-label , phase II study BI 695501 ass handle experience patient Rheumatoid Arthritis use autoinjector . The extension phase provide patient additional exposure BI 695501 enhance safety database compound .</brief_summary>
	<brief_title>Assessment Handling Experience With BI 695501 Autoinjector Patients With Rheumatoid Arthritis Followed Extension Phase Using BI 695501 Prefilled Syringe</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion criterion : Moderately severely active RA least 6 month , adequately control nonbiologics DMARDs . No contraindication antiTNF agent . Either biologics naive biologicsexperienced experience selfadministration medication use autoinjector pen . Patients must able willing selfinject BI 695501 . Further inclusion criterion apply . Exclusion criterion : Experience selfadministration medication use autoinjector pen . American College Rheumatology functional Class IV wheelchair/ bed bound . Primary secondary immunodeficiency . History TB . Further exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>